• Age ≥18 years

• Performance status (ECOG) ≤ 2

• Life expectancy ≥3 months

• Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.

• Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.

• Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to reveive the available treatments.

• Adequate hematological or biochemical parameters as specified below

‣ Hemoglobin \> 8.0 g/dl (without transfusion support within 7 days)

⁃ Platelets count \> 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L.

⁃ Absolute neutrophil count (ANC) \> 0.75 x109/L (without G-CSF support within 7 days)

⁃ Aspartate transaminase (AST): \<2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases)

⁃ Alanine transaminase (ALT): \< 2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases)

⁃ Total bilirubin: \< 2 x the upper limit range.

⁃ Calculated or measured creatinine clearance: \>30 mL/min (calculated from the Cockcroft-Gault formula).

• Left ventricular ejection fraction \> 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.